Fujirebio Diagnostics Announces FDA Clearance of Lumipulse® G CA19-9-N Assay
Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G1200 CA19-9-N assay for testing on its LUMIPULSE® G1200 immunoassay platform. MALVERN, PA. (PRWEB) DECEMBER 17, 2019 Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has[…]
Read more